Lenaerts et al., 2008 - Google Patents
Clinical features and treatment of adenovirus infectionsLenaerts et al., 2008
- Document ID
- 6266413617896784761
- Author
- Lenaerts L
- De Clercq E
- Naesens L
- Publication year
- Publication venue
- Reviews in medical virology
External Links
Snippet
Adenoviruses (Ads) are common opportunistic pathogens that are rarely associated with severe clinical symptoms in healthy individuals. In contrast, in patients with compromised immunity, Ad infections often result in disseminated and potentially life‐threatening disease …
- 208000010370 Adenoviridae Infections 0 title description 13
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses
- C12N2710/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA Viruses dsDNA Viruses
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lenaerts et al. | Clinical features and treatment of adenovirus infections | |
| Lenaerts et al. | Antiviral therapy for adenovirus infections | |
| Krishna et al. | Advances in the treatment of cytomegalovirus | |
| Shukla et al. | Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry | |
| US7186700B2 (en) | β-L-2′-deoxynucleosides for the treatment of resistant HBV strains and combination therapies | |
| Butler et al. | Murine encephalitis caused by HCoV-OC43, a human coronavirus with broad species specificity, is partly immune-mediated | |
| Mercorelli et al. | Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives | |
| Martinez-Aguado et al. | Antiadenovirus drug discovery: potential targets and evaluation methodologies | |
| Wy Ip et al. | Management of adenovirus in children after allogeneic hematopoietic stem cell transplantation | |
| JP2018524977A (en) | Adenovirus polynucleotides and polypeptides | |
| Melnik et al. | Peptide inhibition of human cytomegalovirus infection | |
| McGregor et al. | Cytomegalovirus antivirals and development of improved animal models | |
| CN101426516B (en) | Use of the long pentraxin PTX3 for the prevention or treatment of viral diseases | |
| CN112023045A (en) | Application of substance for inhibiting MASP-2 and downstream complement activation effect thereof in preparation of drugs for treating diseases caused by coronavirus | |
| US20080118471A1 (en) | Constitutive gene expression in conjunction with ionizing radiation | |
| JP4806187B2 (en) | Combination therapy with L-FMAU for the treatment of hepatitis B virus | |
| Abdullah et al. | Cytomegalovirus replication steps and the actions of antiviral drugs | |
| US20130177528A1 (en) | Compositions and methods for inhibiting viral infection | |
| JP7508109B2 (en) | Oncolytic virus based on human adenovirus type 35 | |
| Donofrio et al. | Bovine herpesvirus 4 based vector interaction with liver cells in vitro and in vivo | |
| Bil-Lula et al. | Adenoviral Infection-Common Complication Following Hematopoietic Stem Cell Transplantation | |
| Chi et al. | In vitro and in vivo broad antiviral activity of peptides homologous to fusion glycoproteins of Newcastle disease virus and Marek's disease virus | |
| Bonavita | Functional and Phenotypic Evaluation of Murine Cytomegalovirus Infection of the Heart | |
| Krüger | Novel concepts for the treatment of HSV-2 and other enveloped viruses | |
| Joshi | A comparative analysis of human T cell responses to adenoviral early and late proteins |